Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Dr. Nabanita Mukherjee

Dr. Nabanita Mukherjee
Nabanita Mukherjee
Department of Dermatology
University of Colorado
USA
University of Colorado

Biography

Dr. Mukherjee is currently working as a post-doctoral researcher in the Department of Dermatology at Anschutz Medical Campus, University of Colorado, Denver. The aim of her current research project is to understand the mechanisms involved in melanoma chemoresistance and to develop methods to reverse the resistance of melanoma to therapy with special focus on targeting resistant sub-populations such as melanoma initiating cells (MICs). She is also looking at the role of BCL-2 family of proteins in predicting immunotherapy response/ resistance. Apart from melanoma she is interested in looking at different proteins and transcription factors that can play a role in various skin diseases. She serves as a reviewer in multiple cancer journals. She obtained her PhD degree from University of Vermont. Her dissertation project was designed to look at the effects of chemotherapy drugs on the afferent taste signaling pathway. Previously, she obtained her Bachelors and Master’s degree from University of Calcutta, India.

Research Interest

Dermatology, Melanoma, Immunotherapy, BCL-2 Family of proteins, Cancer stem cells

Top